257 related articles for article (PubMed ID: 26867946)
21. Sonidegib (Odomzo°) and extensive basal cell carcinoma.
Prescrire Int; 2017 Jan; 26(178):14-15. PubMed ID: 30730637
[No Abstract] [Full Text] [Related]
22. Sonidegib in the Treatment of Locally Advanced Basal Cell Carcinoma.
Sanmartín O; Llombart B; Carretero Hernández G; Flórez Menéndez Á; Botella-Estrada R; Herrera Ceballos E; Puig S
Actas Dermosifiliogr (Engl Ed); 2021 Apr; 112(4):295-301. PubMed ID: 33197438
[TBL] [Abstract][Full Text] [Related]
23. Expert opinion on sonidegib efficacy, safety and tolerability.
Villani A; Fabbrocini G; Costa C; Ocampo-Garza SS; Lallas A; Scalvenzi M
Expert Opin Drug Saf; 2021 Aug; 20(8):877-882. PubMed ID: 33888008
[No Abstract] [Full Text] [Related]
24. Vismodegib: A Review in Advanced Basal Cell Carcinoma.
Frampton JE; Basset-Séguin N
Drugs; 2018 Jul; 78(11):1145-1156. PubMed ID: 30030732
[TBL] [Abstract][Full Text] [Related]
25. Odomzo
Gupta AK; Mays RR; Abramovits W; Vincent KD
Skinmed; 2018; 16(1):35-38. PubMed ID: 29551110
[No Abstract] [Full Text] [Related]
26. FDA Approval Summary: Sonidegib for Locally Advanced Basal Cell Carcinoma.
Casey D; Demko S; Shord S; Zhao H; Chen H; He K; Putman A; Helms W; Keegan P; Pazdur R
Clin Cancer Res; 2017 May; 23(10):2377-2381. PubMed ID: 28073840
[TBL] [Abstract][Full Text] [Related]
27. Sonidegib for the treatment of advanced basal cell carcinoma.
Ramelyte E; Amann VC; Dummer R
Expert Opin Pharmacother; 2016 Oct; 17(14):1963-8. PubMed ID: 27538055
[TBL] [Abstract][Full Text] [Related]
28. Sonic Hedgehog Pathway Inhibition in the Treatment of Advanced Basal Cell Carcinoma.
Leavitt E; Lask G; Martin S
Curr Treat Options Oncol; 2019 Nov; 20(11):84. PubMed ID: 31773379
[TBL] [Abstract][Full Text] [Related]
29. Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma.
Proctor AE; Thompson LA; O'Bryant CL
Ann Pharmacother; 2014 Jan; 48(1):99-106. PubMed ID: 24259609
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of sonidegib in histologic subtypes of advanced basal cell carcinoma: Results from the final analysis of the randomized phase 2 Basal Cell Carcinoma Outcomes With LDE225 Treatment (BOLT) trial at 42 months.
Dummer R; Lear JT; Guminski A; Leow LJ; Squittieri N; Migden M
J Am Acad Dermatol; 2021 Apr; 84(4):1162-1164. PubMed ID: 33358380
[No Abstract] [Full Text] [Related]
31. Clinical determinants of clinical response to Sonidegib in advanced basal cell carcinoma: a monocenter experience.
Spallone G; Carbone A; Sperati F; Frascione P; Eibenschutz L
Eur Rev Med Pharmacol Sci; 2024 Apr; 28(7):2923-2928. PubMed ID: 38639529
[TBL] [Abstract][Full Text] [Related]
32. A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors.
Rodon J; Tawbi HA; Thomas AL; Stoller RG; Turtschi CP; Baselga J; Sarantopoulos J; Mahalingam D; Shou Y; Moles MA; Yang L; Granvil C; Hurh E; Rose KL; Amakye DD; Dummer R; Mita AC
Clin Cancer Res; 2014 Apr; 20(7):1900-9. PubMed ID: 24523439
[TBL] [Abstract][Full Text] [Related]
33. Dynamic optical coherence tomography evaluation in locally advanced basal cell carcinoma during sonidegib treatment.
Cantisani C; Musolff N; Longo C; Di Guardo A; Rovaldi E; Rossi G; Sasso F; Farnetani F; Rega F; Bánvölgyiv A; Azzella G; Paolino G; Pellacani G
J Eur Acad Dermatol Venereol; 2024 May; 38(5):967-973. PubMed ID: 38270330
[TBL] [Abstract][Full Text] [Related]
34. Vismodegib and Sonidegib in Locally Advanced and Metastatic Basal Cell Carcinoma: Update on Hedgehog Pathway Inhibitors.
Kurnia Wijaya J; Djawad K; Wahab S; Nurdin A; Irawan Anwar A
Actas Dermosifiliogr; 2022 May; 113(5):443-450. PubMed ID: 35697404
[TBL] [Abstract][Full Text] [Related]
35. U.S. Food and Drug Administration approval: vismodegib for recurrent, locally advanced, or metastatic basal cell carcinoma.
Axelson M; Liu K; Jiang X; He K; Wang J; Zhao H; Kufrin D; Palmby T; Dong Z; Russell AM; Miksinski S; Keegan P; Pazdur R
Clin Cancer Res; 2013 May; 19(9):2289-93. PubMed ID: 23515405
[TBL] [Abstract][Full Text] [Related]
36. Dermatoscopy and locally advanced or multiple basal cell carcinomas: a non-invasive tool to evaluate sonidegib effectiveness.
Conforti C; Toffoli L; Agozzino M; Di Meo N; Zelin E; Zalaudek I
Dermatol Online J; 2021 Sep; 27(9):. PubMed ID: 34755992
[No Abstract] [Full Text] [Related]
37. Sonidegib with and Without Adjunctive Treatment for Locally Advanced Basal Cell Carcinomas.
Villani A; Fabbrocini G; Costa C; Potestio L; Scalvenzi M
Oncologist; 2022 Jun; 27(6):e533. PubMed ID: 35436344
[No Abstract] [Full Text] [Related]
38. Efficacy and safety of sonidegib for the management of basal cell carcinoma: a drug safety evaluation.
Villani A; Scalvenzi M; Micali G; Lacarrubba F; Genco L; Ruggiero A; Fornaro L; Guerrasio G; Potestio L
Expert Opin Drug Saf; 2023; 22(7):525-531. PubMed ID: 37326221
[TBL] [Abstract][Full Text] [Related]
39. Anal and rectal locally advanced basal cell carcinoma treated with sonidegib.
Conforti C; Toffoli L; Degrassi F; di Meo N; Zalaudek I
Dermatol Ther; 2022 Feb; 35(2):e15242. PubMed ID: 34854197
[No Abstract] [Full Text] [Related]
40. Vismodegib: a guide to its use in locally advanced or metastatic basal cell carcinoma.
Lyseng-Williamson KA; Keating GM
Am J Clin Dermatol; 2013 Feb; 14(1):61-4. PubMed ID: 23329081
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
